Validation of Insulin Dose Prediction Model Based on Artificial Intelligence Algorithm
Status:
RECRUITING
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The present study aims to conduct a prospective controlled trial comparing an LSTM-based artificial intelligence (AI) prediction model and clinicians' experience in the efficacy and safety of blood glucose control in hospitalized patients with type 2 diabetes mellitus (T2DM) receiving continuous subcutaneous insulin infusion (CSII) treatment in the Department of Endocrinology. The main question it aims to answer is:
Is the prediction model superior to or (at least) non-inferior to clinicians' experience?
Eligible patients who receive CSII treatment are randomly allocated into the prediction model group and the empirical group. Patients will:
1. Receive CSII treatment as standard of care during hospitalization for 1-2 weeks, where the daily insulin dose regimen is determined by a prediction model or a clinician's experience.
2. Use continuous glucose monitoring (CGM) for glucose tracking.
3. Receive diabetes self-management education covering nutrition and physical activity.